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OBJECTIVE—Accumulating evidence suggests that cyto-
chrome P450 (CYP) epoxygenases metabolize arachidonic acid
into epoxyeicosatrienoic acids (EETs), which play crucial and
diverse roles in cardiovascular homeostasis. The anti-inﬂamma-
tory, antihypertensive, and pro-proliferative effects of EETs
suggest a possible beneﬁcial role for EETs on insulin resistance
and diabetes.
RESEARCH DESIGN AND METHODS—This study investi-
gated the effects of CYP2J3 epoxygenase gene therapy on insulin
resistance and blood pressure in diabetic db/db mice and in a
model of fructose-induced hypertension and insulin resistance in
rats.
RESULTS—CYP2J3 gene delivery in vivo increased EET gener-
ation, reduced blood pressure, and reversed insulin resistance as
determined by plasma glucose levels, homeostasis model assess-
ment insulin resistance index, and glucose tolerance test. Further-
more, CYP2J3 treatment prevented fructose-induced decreases
in insulin receptor signaling and phosphorylation of AMP-acti-
vated protein kinases (AMPKs) in liver, muscle, heart, kidney,
and aorta. Thus, overexpression of CYP2J3 protected against
diabetes and insulin resistance in peripheral tissues through
activation of insulin receptor and AMPK pathways.
CONCLUSIONS—These results highlight the beneﬁcial roles of
the CYP epoxygenase-EET system in diabetes and insulin
resistance. Diabetes 59:997–1005, 2010
A
rachidonic acid is liberated from cell mem-
branes by phospholipases in response to vari-
ous stimuli and is subsequently metabolized by
three different enzyme pathways, namely the
cyclooxygenase, the lipoxygenase, and the cytochrome
P450 (CYP) epoxygenase pathways. Metabolism of arachi-
donic acid via CYP epoxygenases produces four different
cis-epoxyeicosatrienoic acids (EETs): 5,6-, 8,9-, 11,12-, and
14,15-EET. Human P450 2J2 (CYP2J2) and its rat homolog
CYP2J3 are predominant enzymes responsible for the
oxidation of endogenous arachidonic acid pools in cardiac
myocytes, vascular endothelium, pancreas, and other tis-
sues where they exert regulatory effects in normal and
pathophysiological processes (1–4).
Accumulating evidence suggests that EETs play crucial
and diverse roles in cardiovascular homeostasis. Arachi-
donic acid epoxygenase metabolites stimulate endothelial
cell growth and angiogenesis via mitogen-activated protein
kinase (MAPK) and phosphatidylinositol 3-kinase (PI 3-ki-
nase)/AKT signaling pathways, and to some extent, the
endothelial NO synthase (eNOS) pathway (5). Moreover,
EETs upregulate eNOS in bovine aortic endothelial cells
via activation of MAPK, protein kinase C, PI 3-kinase/AKT,
and MAPK signaling pathways (6,7). CYP epoxygenase
overexpression, which increases EET biosynthesis, signif-
icantly protects endothelial cells from apoptosis induced
by tumor necrosis factor- (TNF-), an effect that is
mediated, at least in part, through inhibition of MAPK
dephosphorylation and activation of PI 3-kinase/AKT path-
ways (8). Furthermore, CYP-derived eicosanoids are vaso-
dilatory, at least in part through their ability to activate
eNOS and NO release (9).
Considerable experimental evidence suggests that
eNOS-derived NO is a pivotal regulator of blood pressure,
vascular tone, and vascular homeostasis (10–14). Experi-
mental evidence also suggests that NO is involved in the
pathogenesis of diabetes and insulin resistance. NADPH
oxidases in the vascular wall are activated in diabetes,
leading to enhanced degradation of NO and the production
of reactive oxygen species (15). Uncoupling of eNOS has
been demonstrated in animal models of diabetes (16), and
endogenous NO synthase inhibitors including asymmetric
dimethylarginine are an important cause of vascular insu-
lin resistance (17). Cumulatively, these data indicate that
diabetes and insulin resistance are characterized, to some
degree, by endothelial dysfunction, altered eNOS expres-
sion, and NO production. Insulin mediates its effects
through binding to insulin receptors and triggering down-
stream signaling pathways, of which the most important is
the PI 3-kinase/AKT pathway. This pathway is involved in
a variety of insulin responses including protection from
apoptosis and transport of glucose through cell mem-
branes in endothelial cells (8,18).
We hypothesized that overexpression of CYP2J3 and
the subsequent increase in production of EETs might be
beneﬁcial in attenuating hypertension and insulin resis-
tance. Thus, the present study investigated the effects and
underlying mechanisms of CYP2J3 gene therapy on insulin
resistance and diabetes in fructose-induced insulin resis-
tance in rats and in diabetic db/db mice.
RESEARCH DESIGN AND METHODS
Materials and reagents. Materials were obtained from the following suppli-
ers: Antibodies involved in this study were from Santa Cruz Biotechnology
(Santa Cruz, CA); the rabbit polyclonal anti-CYP2J3 antibody was developed
in our laboratory as described (4); fructose, glucose, triglyceride, and choles-
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Rat/Mouse Insulin ELISA Kit was from Linco Research (St. Charles, MO);
14,15-DHET ELISA Kit was from Detroit R&D (Detroit, MI); and guanosine
3,5-cyclic monophosphate (cGMP) and cAMP ELISA kit was from Cayman
Chemical (Ann Arbor, MI). All other chemicals and reagents were purchased
from Sigma-Aldrich unless otherwise speciﬁed. Full-length CYP2J3 cDNA was
cloned from rat liver RNA and then subcloned into the pcDNA plasmid vector
in sense (CYP2J3
) and antisense (CYP2J3
) orientations.
Animals. All animal experimental protocols complied with standards stated
in the National Institutes of Health Guidelines for the Care and Use of
Laboratory Animals and were approved by The Academy of Sciences of
China. Male Sprague-Dawley rats weighing 200  20 g and male C57BL/6 and
db/db mice (8 weeks old) were obtained from the Experimental Animal Center
of Shanghai (Shanghai, People’s Republic of China). Animals were treated
before experiments as described previously (19).
Fructose feeding and gene delivery protocols. After a 1-week adaptation
period (i.e., beginning at week 0), rats were fed normal rat chow and either
normal water (n  32) or water containing 10% fructose (n  24) for a total of 5
weeks. Systolic blood pressure was measured weekly until week 6, and gene
delivery protocols were undertaken at week 3 as described previously (19).
For the mouse study, C57BL/6 and db/db mice were anesthetized with
diethyl ether and received a sublingual vein injection of plasmid at a dose of
5 mg/kg body wt. C57BL/6 mice received either empty pcDNA (C57BL/6 
pcDNA), CYP2J3
 (C57BL/6  CYP2J3
), or 0.9% NaCl (C57BL/6 normal)
(n  8 per group), and db/db mice similarly received either pcDNA (db/db 
pcDNA), CYP2J3
 (db/db  CYP2J3
), or 0.9% NaCl (db/db normal) (n  8 per
group).
Blood pressure measurement. Systolic blood pressure was measured
weekly in conscious rats with a manometer-tachometer (Rat Tail NIBP
System; ADI Instruments, Bella Vista, NSW, Australia) using the tail-cuff
method as described previously (19).
Rat serum and urine analyses. Serum and urine samples from all rats were
collected. Fasting serum levels of insulin, glucose, sodium, potassium, mag-
nesium, cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol as
well as urine levels of sodium, potassium, and magnesium were assessed as
described previously (19). Similarly, serum and urine samples from all mice
were collected, and serum levels of insulin, glucose, cholesterol, triglycerides,
LDL cholesterol, and HDL cholesterol were assessed. Serum levels of alanine
aminotransferase, urea, and creatinine in rats were also measured on an
AEROSET Clinical Chemistry System (Abbott Laboratories) to evaluate renal
and liver function. Additional details are provided in the supplementary
methods, available in an online appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-1241/DC1.
Glucose tolerance test. At 2 weeks after gene delivery, C57BL/6 and db/db
mice were fasted overnight (for 16 h) and then injected intraperitoneally with
D-glucose (20% solution; 2 g/kg body wt). At 0, 30, 60, and 120 min after glucose
administration, blood samples were taken from the cavernous sinus with a
capillary while under ether anesthesia. Plasma glucose and insulin levels were
determined using methods identical to those used for serum samples in rats
(described in detail in the online supplementary methods).
Evaluation of urine 14,15-DHET by ELISA. To assess in vivo EET
production, an ELISA kit (Detroit R&D) was used to determine concentrations
of the stable EET metabolite 14,15-dihydroxyeicosatrienoic acid (14,15-
DHET) in the urine of rats and mice. 14,15-DHET was quantiﬁed by enzyme-
linked immunosorbent assay (ELISA) according to the manufacturer’s
instructions, as previously described (7).
RT-PCR analysis of aortic ET-1 and ETA-R mRNA. Total RNA was
extracted from frozen rat aortas using TRIZOL reagent (Invitrogen, Carlsbad,
CA) and used to assess mRNA levels of ET-1 and ETA-R. The following
oligonucleotide primers were used for ampliﬁcation of the ET-1 and ETA-R
cDNAs from reverse-transcribed aortic RNA: ET-1 (forward): 5-AAGCGTT-
GCTCCTGCTCCTCC-3; ET-1 (reverse): 5-TTCCCTTGGTCTGGTCTTTGTG-
3; ETA-R (forward): 5-TGCTCAACGCCACGACCAAGT-3; ETA-R (reverse):
5-GGTGTTCGCTGAGGGCAATCC-3.
Ampliﬁcation was performed on an ABI7500 PCR system (Applied Biosys-
tems, Darmstadt, Germany) after incubation with Moloney murine leukemia
virus reverse transcriptase at 42°C for 15 min. A preheating step of 5 min at
95°C was followed by 40 cycles consisting of 30 s at 95°C, 20 s at 60°C, and 20 s
at 72°C. PCR products were electrophoresed on 1.5% agarose gels. The
quantities of speciﬁc ET-1 and ETA-R transcripts were normalized to levels of
glyceraldehyde-3-phosphate dehydrogenase transcripts to control for RNA
quality and amount.
Western blot analysis. At 2 weeks after gene injection, rats and mice from
each group were anesthetized with pentobarbital (100 mg/kg i.p.), and skeletal
muscles, aortas, hearts, kidneys, and livers were excised, frozen in liquid nitrogen,
and stored at 80°C. Western blotting was performed as described previously
(19). Expression was quantiﬁed by densitometry and normalized to -actin
expression. All groups were then normalized to their respective controls, and bar
graphs represent quantiﬁcation of at least three independent experiments.
Evaluation of urinary cAMP and cGMP by ELISA. Urinary cAMP and
cGMP levels were measured by ELISA as previously described (20,21).
Statistical analysis. Continuous data were expressed as means  SEM.
Comparisons between groups were performed by a one-way ANOVA. Two-
way ANOVA was used to examine differences in response to treatments and
between groups, with post hoc analyses performed using the Student-
Newman-Keuls test. Statistical signiﬁcance was deﬁned as P  0.05.
RESULTS
Blood pressure and metabolic changes in fructose-
treated rats. All rats in the study were assessed for a
variety of physiological parameters 3 weeks after receiving
either control or fructose-containing drinking water. As
expected, consumption of fructose-containing water re-
sulted in signiﬁcantly increased systolic blood pressure,
signiﬁcantly increased levels of serum insulin, serum tri-
glyceride, urine potassium, urine magnesium, and urine
volume, and signiﬁcantly decreased urine osmolarity (all
P  0.05) (Table 1, Fig. 1, and supplementary Table 1).
Homeostasis model assessment insulin resistance (HOMA-
IR) also was signiﬁcantly increased in fructose-treated rats
(P  0.05) (Table 1). These data indicate that fructose
administration induced hypertension, insulin resistance,
and hypo-osmolar diuresis as described previously (19).
Effects of CYP2J3 gene delivery on CYP2J3 protein
expression and on fructose-induced hypertension
and pathophysiological changes in rats. At 2 weeks
after gene delivery (i.e., at week 5 of the study), CYP2J3
protein levels were increased in the aorta, heart, liver, and
kidney of fructose-treated CYP2J3
 (F  CYP2J3
) rats
compared with fructose-treated rats injected with CYP2J3

or with the empty pcDNA vector (Fig. 1A). Importantly,
CYP2J3 functionality was demonstrated by the nearly four-
fold increase in urinary 14,15-DHET levels in rats injected
with CYP2J3
 compared with those injected with CYP2J3

or with the empty pcDNA vector (Fig. 1B).
Injection of CYP2J3
 to fructose-treated rats resulted in
decreased systolic blood pressure 1, 2, and 3 weeks after
injection (i.e., at weeks 4, 5, and 6 of the study, respec-
tively) compared with that observed in fructose-treated
rats injected with the control pcDNA or CYP2J3
 vectors
(Fig. 1C). The maximum reduction in blood pressure in F
 CYP2J3
 rats was observed 2 weeks after injection (i.e.,
at week 5 of the study) when blood pressure reached a
level similar to those observed in rats drinking normal
water (Fig. 1C). No changes in blood pressure compared
TABLE 1
Physiological parameters determined in rats after 3 weeks of
administration of control or fructose-containing drinking water
Variables
Control group
(n  32)
Fructose-treated
group (n  24)
Glucose (mmol/l) 4.91  0.2 5.62  0.4
Triglycerides (mmol/l) 0.45  0.12 1.18  0.47*
Insulin (mIU/l) 17.74  0.59 49.11  0.42†
HOMA-IR 4.21  0.56 14.24  0.86†
Body weight (g) 254  33 267  26
Physiological parameters determined in rats after 3 weeks of admin-
istration of normal or fructose-containing drinking water. Fasting
triglyceride, insulin levels, and HOMA-IR were increased in fructose-
treated rats after 3 weeks of administration of fructose-containing
drinking water. Values shown are mean  SE from each group of
rats, respectively. *P  0.05, †P  0.001 compared with rats treated
with water.
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water–treated rats administered pcDNA, CYP2J3
,o r
CYP2J3
 (Fig. 1C). These data indicate that CYP2J3 overex-
pression reduced hypertension in fructose-treated rats but
had no effect on blood pressure in normal control rats.
Other physiological and biochemical parameters related
to hypertension and hyperinsulinemia were assessed in
eight rats per experimental group 2 weeks after gene
delivery (week 5) (Table 2 and supplementary Table 2).
Compared with values in the normal water–treated
groups, serum insulin, insulin resistance (HOMA-IR), se-
rum triglycerides, urine volume, urine potassium, and
urine magnesium levels were all higher, whereas urine
osmolarity was lower in fructose-treated rats injected with
the empty pcDNA vector (F  pcDNA group; all P  0.05)
(Table 2 and supplementary Table 2). With the exception
of serum triglyceride levels, all of these changes were
prevented by injection of fructose-treated rats with
CYP2J3
, but not with CYP2J3
 (Table 2 and supplemen-
tary Table 2). These data indicate that CYP2J3 overexpres-
sion markedly attenuated fructose-induced insulin
resistance in rats but that it had no effect on these
parameters in normal water–treated rats.
Compared with values in the normal water–treated
groups, serum alanine aminotransferase, urea nitrogen, and
creatinine showed no signiﬁcant changes in fructose-treated
rats injected with the empty pcDNA vector (F  pcDNA
group; all P 	 0.05). Compared with values in rats injected
with empty pcDNA vector, serum alanine aminotransferase,
urea nitrogen, and creatinine were not signiﬁcantly changed
in rats injected with CYP2J3
 (supplementary Table 3).
These data indicate that CYP2J3 overexpression has no
detrimental effects on rat renal and liver function.
Effects of CYP2J3 gene delivery on rat insulin recep-
tor signaling and eNOS, ET-1, and ETA-R expression.
PI 3-kinase is recruited to insulin receptor substrate (IRS)
signaling complexes through binding of Src homology 2
domains in its 85-kDa regulatory subunit to speciﬁc phos-
photyrosine residues in IRS-1, a process that leads to
activation of the PI 3-kinase p110 catalytic subunit (22). To
investigate the signaling mechanisms through which
CYP2J3 attenuates fructose-induced insulin resistance, we
evaluated the expression of IRS-1 associated with the
insulin signaling cascade in rat liver and skeletal muscle.
Compared with levels in normal control rats, fructose
drinking resulted in signiﬁcantly decreased IRS-1 levels in
liver and skeletal muscle (Fig. 2A and B). Phospho-Y989-
IRS-1 levels were similarly decreased in liver and
skeletal muscle, whereas phospho-S307-IRS-1 was sig-
niﬁcantly increased (supplementary Fig. 1A and B).
Administration of CYP2J3
 signiﬁcantly reversed the
changes in IRS-1 and phospho–IRS-1 levels induced by
fructose in both liver and skeletal muscle (Fig. 2A and B;
supplementary Fig. 1A and B).
Compared with expression in corresponding control
animals, eNOS protein expression was downregulated in
aorta, liver, and skeletal muscle in fructose-treated rats;
this effect was not observed in fructose-treated rats in-
jected with CYP2J3
 (Fig. 2C; supplementary Fig. 1C and
D). Similar changes in eNOS expression and effects of
CYP2J3
 were observed in rat heart and kidney (data not
shown). These data suggest that CYP2J3
 treatment re-
stored eNOS activity and support previous observations of
a beneﬁcial effect of eNOS against fructose-induced hyper-
tension and hyperinsulinemia (23).
The expression of ET-1 and ETA-R mRNA transcripts in
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FIG. 1. Effects of CYP2J3 gene delivery on CYP2J3 protein expression,
urinary 14,15-DHET levels, and fructose-induced hypertension in rats.
A: CYP2J3 protein levels were increased in aorta (A), heart (H),
liver (L), and kidney (K) of fructose-treated rats 2 weeks after
injection of CYP2J3
 but not after injection of CYP2J3
 or empty
vector (pcDNA). B: Urinary 14,15-DHET levels were increased in
control and fructose-treated rats injected with CYP2J3
 compared
with rats injected with CYP2J3
 or empty vector (pcDNA). *P < 0.01
versus pcDNA; #P < 0.01 versus CYP2J3
; n  8 per group. C: The
elevation of systolic blood pressure (BP) observed in fructose-
treated rats was decreased 1, 2, and 3 weeks after injection of
CYP2J3
 (i.e., at weeks 4, 5, and 6 of the study, respectively) but not
after injection with CYP2J3
 or empty vector (pcDNA). Values
shown are mean  SEM from each group of rats. *P < 0.01 compared
with rats treated without fructose, #P < 0.01 compared with rats
treated with fructose, **P < 0.01 compared with rats treated with
CYP2J3
; n  4–10 per group per time point.
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delivery to examine the effects of fructose feeding and
CYP2J3 gene delivery on the endothelin pathway, which
has been shown to play a role in blood pressure homeosta-
sis. Fructose administration resulted in signiﬁcant in-
creases in aortic ET-1 and ETA-R mRNA levels (Fig. 2D
and E). These changes were prevented in rats adminis-
tered CYP2J3
, but not in rats administered CYP2J3
.
Effects of CYP2J3 gene delivery on CYP2J3 protein
expression and on pathophysiological changes and
glucose tolerance in db/db mice. Similar to observa-
tions in fructose-fed rats, levels of CYP2J3 protein were
increased in the aorta, heart, liver, and kidney in diabetic
db/db mice 2 weeks after injection with CYP2J3
 com-
pared with levels observed after injection with the empty
pcDNA vector (Fig. 3A). Functionality of the CYP2J3
TABLE 2
Physiological parameters determined in rats 2 weeks after injection of empty pcDNA3.1 vector, pcDNA-2J3
, or pcDNA-2J3

Variables
Treatment group
Normal water treated
Normal
Fructose treated
N  pcDNA3.1 N  p2J3
 N  p2J3
 F  pcDNA3.1 F  p2J3
 N  p2J3

Glucose (mmol/l) 5.36  0.68 6.99  0.06 5.69  0.86 5.09  0.36 6.55  0.58 6.44  0.68 6.85  0.99
Triglycerides (mmol/l) 0.61  0.22 0.63  0.39 0.45  0.18 0.53  0.09 1.04  0.89* 1.30  0.13 1.26  0.4
Insulin (mIU/l) 22.65  0.94 18.16  0.81 18.83  0.44 20.5  0.64 49.71  0.71* 19.48  0.18† 60.25  0.08‡
HOMA-IR 5.26  0.82 4.16  0.36 6.64  0.61 5.06  0.26 14.25  0.02* 5.40  0.59† 24.28  0.04‡
Body weight (g) 310  34 311  49 307  35 299  40 297  49 303  31 341  65
Compared with values in the normal water–treated groups, serum insulin, insulin resistance (HOMA-IR), and serum triglycerides levels were
all higher in fructose-treated rats injected with the empty pcDNA vector (F  pcDNA group). With the exception of serum triglyceride levels,
all of these changes were prevented by injection of fructose-treated rats with CYP2J3
 but not CYP2J3
.* P  0.05 vs. N  pcDNA3.1 group;
†P 0.05 vs. F  pcDNA3.1 group; ‡P  0.05 vs. F  p2J3
 group; n  8 per group.
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FIG. 2. Expression of IRS-1, eNOS, ET-1, and ETA-R in fructose-treated rats. Fructose administration to rats resulted in signiﬁcantly decreased IRS-1
protein levels in liver (A) and skeletal muscle (B) and signiﬁcantly decreased eNOS protein levels in aorta (C). These effects were inhibited by injection
of CYP2J3
, but not by injection of CYP2J3
. Representative Western blots are shown above graphs summarizing densitometric quantiﬁcation. *P <
0.05 versus N  pcDNA; #P < 0.05 versus F  pcDNA; **P < 0.05 versus F  CYP2J3
; n  8 per group. Levels of ET-1 (D) and ETA-R (E) transcripts
relative to glyceraldehyde-3-phosphate dehydrogenase were assessed by RT-PCR in aortic tissue samples from three rats from each treatment group
at week 5 of the study. Representative RT-PCR of ET-1 or ETA-R mRNA expression and corresponding densitometric quantiﬁcation of three
experiments are shown. Values shown are mean  SEM. *P < 0.05 versus N  pcDNA3.1; #P < 0.05 versus F  pcDNA3.1; **P < 0.05 versus F 
pcDNA-CYP2J3
. Effects of CYP2J3 gene delivery on rat insulin receptor signaling and eNOS expression. Fructose administration to rats resulted in
signiﬁcantly decreased eNOS protein levels in aorta (C) and decreased IRS-1 protein levels in liver (D) and skeletal muscle (E). These effects were
inhibited by injection of CYP2J3
, but not by injection of CYP2J3
. Representative Western blots are shown above graphs summarizing densitometric
quantiﬁcation. *P < 0.05 versus N  pcDNA; #P < 0.05 versus F  pcDNA; **P < 0.05 versus F  CYP2J3
; n  8 per group.
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ﬁvefold increase in urinary 14,15-DHET levels in both
C57BL/6 and db/db mice injected with CYP2J3
 compared
with those injected with the empty pcDNA vector (Fig.
3B).
The diabetic phenotype of db/db mice (injected with the
empty pcDNA vector) was conﬁrmed by signiﬁcantly
higher levels of serum glucose, serum insulin, insulin
resistance (HOMA-IR), serum triglycerides, serum choles-
terol, and urine volume in these animals compared with
those in C57BL/6 mice (all P  0.05; Table 3 and supple-
mentary Table 4). Injection of CYP2J3
 signiﬁcantly re-
duced insulin resistance (HOMA-IR) and urine volume in
db/db mice, whereas injection of the empty pcDNA vector
did not (Table 3 and supplementary Table 4). Although not
all parameters of the diabetic phenotype in db/db mice
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FIG. 3. Effects of CYP2J3 gene delivery on CYP2J3 protein expression, urinary 14,15-DHET levels, and glucose tolerance in db/db mice. A: Levels
of CYP2J3 protein were increased in the aorta (A), heart (H), liver (L), and kidney (K) in diabetic db/db mice 2 weeks after injection with
CYP2J3
 compared with levels observed after injection with the empty pcDNA vector. B: Urinary 14,15-DHET levels were increased in C57BL/6
and db/db mice injected with CYP2J3
 compared with those injected with the empty pcDNA vector. *P < 0.05 versus control and pcDNA-treated
mice of corresponding genotype; n  8 per group. Blood glucose (C) and plasma insulin (D) levels before and up to 120 min after a single glucose
challenge were elevated in db/db mice and decreased by injection with CYP2J3
. No such reduction was observed in db/db mice injected with
empty vector (pcDNA). *P < 0.05 versus C57BL/6; #P < 0.05 versus db/db  pcDNA; n  8 per group.
TABLE 3
Physiological parameters determined in mice 2 weeks after injection of empty pcDNA3.1 vector or pcDNA-2J3

Variables C57BL/6
C57BL/6 
pcDNA3.1
C57BL/6 
p2J3
 db/db
db/db 
pcDNA3.1
db/db 
p2J3

Glucose (mmol/l) 10.48  0.57 9.78  0.38 9.70  0.60 21.99  1.83* 23.19  2.51* 23.15  2.36
Triglycerides (mmol/l) 1.2  0.15 1.5  0.22 1.43  0.14 2.26  0.28* 2.63  0.00.32* 2.57  0.37
Insulin (mIU/l) 2.06  0.35 2.13  0.36 1.46  0.31 7.66  1.33* 7.25  0.87* 8.25  1.96
Fasting glucose (mmol/l) 5.54  0.33 5.67  0.26 5.18  0.40 17.52  3.20* 18.80  2.35* 12.65  1.14†
Fasting insulin (ng/ml) 0.23  0.02 0.22  0.03 0.23  0.01 2.49  0.57* 2.618  0.19* 1.43  0.36†
HOMA-IR 0.053  0.006 0.055  0.005 0.052  0.002 2.19  0.72* 2.26  0.45* 0.81  0.24†
Body weight (g) 25.48  0.61 25.45  0.68 25.27  0.47 45.16  0.91 45.06  0.97 45.78  1.57
Serum glucose, serum insulin, insulin resistance (HOMA-IR), and serum triglyceride levels were signiﬁcantly higher in the diabetic phenotype
of db/db mice (injected with the empty pcDNA vector) compared with those in C57BL/6 mice. Injection of CYP2J3
 signiﬁcantly reduced
insulin resistance (HOMA-IR) in db/db mice, whereas injection of the empty pcDNA vector did not. *P  0.05 vs. C57BL/6 group; †P  0.05
vs. db/db  pcDNA3.1 group; n  8 per group.
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 treatment, these data provide
further evidence that CYP2J3 can attenuate insulin resis-
tance in this animal model.
A glucose tolerance test was performed in C57BL/6 and
db/db mice 2 weeks after gene delivery. Fasting plasma
glucose levels before glucose loading and plasma glucose
levels after glucose loading were not altered by the various
gene therapy treatments in C57BL/6 mice (Fig. 3C). Com-
pared with levels in C57BL/6 mice, fasting plasma glucose
levels before glucose loading and plasma glucose levels
after glucose loading were signiﬁcantly higher in all db/db
mouse groups. However, the glucose levels before and
after glucose loading in db/db  CYP2J3
 mice were
signiﬁcantly lower than those in the db/db control and
db/db  pcDNA groups (P  0.05) (Fig. 3C). A similar
proﬁle for fasting plasma insulin levels and for plasma
insulin levels after glucose loading was observed, with
db/db  CYP2J3
 mice having levels lower than those of
the other db/db groups but higher than those of all of the
C57BL/6 groups at all time points assessed (Fig. 3D).
These data indicate that CYP2J3 gene delivery attenuated
insulin resistance and has antidiabetic effects in db/db
mice.
Effects of CYP2J3 gene delivery on activation of
mouse insulin receptor signaling and eNOS phos-
phorylation. Similar to the effects of fructose drinking on
rats, S307 IRS-1 phosphorylation was signiﬁcantly in-
creased and Y989-IRS-1 phosphorylation was signiﬁcantly
decreased in livers of db/db control and db/db  pcDNA
mice relative to C57BL/6 mice (Fig. 4A). Similar effects
were observed in skeletal muscle (supplementary Fig. 2A).
Administration of CYP2J3
 to db/db mice prevented these
changes in both tissues (Fig. 4A; supplementary Fig. 2A).
The effects of CYP2J3
 treatment on the phosphoryla-
tion status of eNOS were examined in liver and skeletal
muscle. The level of phospho-T495-eNOS was higher but
phospho-S1177-eNOS was lower in livers of db/db mice
compared with C57BL/6 mice (Fig. 4B). CYP2J3 gene
delivery prevented the downregulation of phospho-S1177-
eNOS but had no impact on phospho-T495-eNOS (Fig. 4B).
Similar results were found in skeletal muscle (supplemen-
tary Fig. 3B), heart, and kidney (data not shown). These
results suggest that CYP2J3
 treatment in db/db mice
altered eNOS phosphorylation status.
Effects of CYP2J3 gene delivery on intracellular
signaling pathways in rats and mice. To investigate
potential mechanisms underlying the observed effects of
CYP2J3
 treatment in rats, the protein expression levels of
a variety of intracellular signaling pathway molecules were
investigated in liver, skeletal muscle, heart, and kidney of
rats and mice in all treatment groups 2 weeks after gene
delivery. The signaling molecules that were assessed in-
cluded PI 3-kinase, phosphorylated AKT (P-T308-AKT),
phosphorylated AMP-activated protein kinases (P-T172-
AMPKs), and phosphorylated p42/44 MAPK (P-MAPK). A
similar pattern of expression was observed for all four
molecules in all four tissues that were examined. Speciﬁ-
cally, tissue protein levels of the speciﬁed signaling mole-
A
pS307-IRS-1
pY989-IRS-1
IRS-1
1.5
CYP2J3(+)
pcDNA
- -
-
- - +
+ +
+
- - -
C57BL/6 db/db
0
1.0
I
R
S
-
1
(
p
S
3
0
7
)
/
I
R
S
-
1
(
R
e
l
a
t
i
v
e
 
I
n
t
e
n
s
i
t
y
)
I
R
S
-
1
(
p
Y
9
8
9
)
/
I
R
S
-
1
(
R
e
l
a
t
i
v
e
 
I
n
t
e
n
s
i
t
y
)
0.5
* *
#
B
pS1177-eNOS
pT495-eNOS
eNOS
CYP2J3(+)
pcDNA
- -
-
- - +
+ +
+
0
1.0
1.5
p
S
1
1
7
7
-
e
N
O
S
/
e
N
O
S
(
R
e
l
a
t
i
v
e
 
I
n
t
e
n
s
i
t
y
)
0.5
- - -
C57BL/6 db/db
0
2
3
p
T
4
9
5
-
e
N
O
S
/
e
N
O
S
(
R
e
l
a
t
i
v
e
 
I
n
t
e
n
s
i
t
y
)
1
4
5
* *
#
* *
* *
#
0
1
2
3
4
5
FIG. 4. Effects of CYP2J3 gene delivery on activation of mouse insulin receptor signaling and eNOS phosphorylation. A: Relative to levels in
C57BL/6 mice, Y989-IRS-1 phosphorylation was signiﬁcantly decreased and S307-IRS-1 phosphorylation signiﬁcantly increased in livers of db/db
normal and db/db  pcDNA mice. These changes were prevented in db/db mice injected with CYP2J3
. Representative Western blots are shown
above graphs summarizing densitometric quantiﬁcation. *P < 0.05 versus C57BL/6; #P < 0.05 versus db/db  pcDNA; n  8 per group. B: Levels
of pS1177-eNOS in liver were lower and levels of pT495-eNOS were higher in db/db mice than in C57BL/6 mice. The downregulation of
pS1177-eNOS was inhibited by injection with CYP2J3
, whereas no effect was observed on pT495-eNOS. Representative Western blots are shown
above graphs summarizing densitometric quantiﬁcation. *P < 0.05 versus C57BL/6; #P < 0.05 versus db/db  pcDNA; n  8 per group.
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and db/db mice compared with levels in normal water–fed
rats and C57BL/6 mice, respectively. The only fructose-
treated rats or db/db mice in which these decreases were
not observed were those that had been injected with
CYP2J3
. PI 3-kinase (P110) expression level data for rat
and mouse liver are shown in Fig. 5A and B, whereas data
for PI 3-kinase in rat and mouse liver and skeletal muscle
and for P-AKT, AMPK, and P-MAPK are shown in supple-
mentary Figs. 4–6. CYP2J3
 injection reversed changes in
protein expression and phosphorylation seen in db/db
mice or induced by fructose in rats. The notable exception
to this pattern was that of P-MAPK in rat tissues, in which
fructose feeding did not result in a decreased level of
P-MAPK; however, CYP2J3
 injection nonetheless in-
creased expression of P-MAPK (supplementary Fig. 6A
and B). Similar results were found for all of these signaling
molecules in heart and kidney of rats and mice (data not
shown). These data suggest that reversal of insulin resis-
tance by CYP2J3
 treatment was associated with restora-
tion of these important intracellular signaling molecules to
normal levels.
Effects of CYP2J3 gene delivery on urinary cAMP and
cGMP levels. To investigate potential mechanisms under-
lying the observed effects of CYP2J3 on the upregulation of
AMPK phosphorylation, cAMP and cGMP levels were
determined in urine of rats in all treatment groups 2 weeks
after gene delivery. Compared with rats treated with
normal water, the concentration of urinary cAMP and
cGMP decreased signiﬁcantly in rats with fructose water
treatment. Interestingly, CYP2J3 gene delivery signiﬁ-
cantly increased urinary cAMP and cGMP level in rats
treated with both normal water and fructose water (Fig.
6A and B). These data indicate that CYP2J3 overexpres-
sion induced a signiﬁcant increase in urine cAMP and
cGMP secretion, which may result from G-protein–cou-
pled receptor (GPCR) activation by EETs.
DISCUSSION
This study was undertaken to examine the effects of
CYP2J3 gene delivery on insulin resistance and diabetes in
fructose-induced insulin-resistant rats and db/db diabetic
mice. Results showed that a single intravenous injection of
CYP2J3 in the eukaryotic expression plasmid pcDNA
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FIG. 5. Effects of CYP2J3 gene delivery on liver PI 3-kinase (PI3K)
expression in fructose-treated rats and mice. A: Decreased liver PI
3-kinase protein levels were observed in fructose-treated rats, and this
was prevented by injection of CYP2J3
, but not by injection of
CYP2J3
 or empty vector (pcDNA). *P < 0.05 versus N  pcDNA; #P <
0.05 versus F  pcDNA; **P < 0.05 versus F  CYP2J3
; n  8 per
group. B: Liver PI 3-kinase protein levels were decreased in db/db mice
compared with C57BL/6 mice. This decrease was prevented by injection
of CYP2J3
 but not by injection of empty vector (pcDNA). *P < 0.05
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FIG. 6. Effects of CYP2J3 gene delivery on urinary cAMP and cGMP
levels. A: Levels of urinary cAMP were increased in rats 2 weeks after
injection with CYP2J3
 compared with levels observed after injection
with the empty pcDNA3.1 vector. B: Urinary cGMP levels were in-
creased in rats injected with CYP2J3
 compared with those injected
with the empty pcDNA vector. *P < 0.05 versus pcDNA-treated and
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sensitivity to insulin in peripheral tissues and organs in
both animal models. CYP2J3 overexpression signiﬁcantly
reduced blood pressure with upregulated eNOS expres-
sion and downregulated ET-1 and ETA expression. Fur-
thermore, CYP2J3 overexpression signiﬁcantly improved
insulin resistance in fructose-induced insulin-resistant rats
and db/db diabetic mice, at least in part through eNOS,
IRS-1, and PI 3-kinase/AKT signaling pathways, as well as
AMPK signaling pathways in liver, muscle, heart, and
kidney. These data provide direct evidence that CYP2J3-
derived EETs may alleviate insulin resistance through a
variety of beneﬁcial effects on critical intracellular signal-
ing pathways.
Previous studies have demonstrated that rats treated
with high-fructose drinking water develop systemic hyper-
tension, hyperinsulinemia, and hypertriglyceridemia (24).
Although the pathophysiological mechanisms responsible
for elevated blood pressure and hyperinsulinemia in fruc-
tose-treated animals are not completely understood, ele-
vated sympathetic nervous system activity, impaired
endothelium-dependent dilation, reduction of capillary
permeability, elevated vascular expression of ET-1 and
ETA receptor genes, decreased eNOS activity, and in-
creased salt absorption by the intestine and kidney have
all been implicated (12,23,25). Polymorphisms in CYP2J2
(the human homolog of CYP2J3) have been associated
with essential hypertension (26), and reduced renal CYP-
derived eicosanoid synthesis has been reported in rats
with high-fat diet–induced hypertension (27). Further-
more, EETs have direct vasodilatory activity (28,29). In the
present study, CYP2J3 overexpression signiﬁcantly ele-
vated urinary levels of 14,15-DHET in rats and mice and
attenuated fructose-induced changes in eNOS, ET-1, and
ETA-R expression in rats. These effects may underlie the
beneﬁcial effects of CYP2J3 overexpression on blood
pressure and hyperinsulinemia that we observed.
Fructose induces inﬂammatory changes in human aortic
endothelial cells and vessel walls in rats (30,31). Cytokines
such as TNF- induce insulin resistance in endothelial
cells via a p38 mitogen–activated protein kinase–depen-
dent pathway (32). This inﬂammatory signaling is relevant
to diabetes, as TNF receptor 1 blockade protects Wistar
rats from diet-induced obesity and insulin resistance (33).
Physiological concentrations of EETs or overexpression
of CYP2J2 decreases cytokine-induced endothelial cell
adhesion molecule expression, indicating that EETs have
anti-inﬂammatory properties independent of their mem-
brane-hyperpolarizing effects (34). Furthermore, increased
NO release improves insulin resistance in fructose-treated
rats (23,35). Potassium depletion in rats exacerbates en-
dothelial dysfunction and lowers the bioavailability of NO,
which blocks insulin activity and causes insulin resistance
(35). We observed that CYP2J3 expression resulted in a
signiﬁcant reduction in urine volume and urine potassium
in fructose-treated rats. This suggests a potential amelio-
rative effect of CYP2J3 treatment against hypertension-
related end organ (kidney) damage and attenuation of
insulin resistance.
The precise molecular mechanisms for attenuation of
insulin resistance in CYP2J3-injected, fructose-treated
rats remain to be elucidated. Recent studies indicate that
the ability of insulin to vasodilate skeletal muscle vascu-
lature is mediated by endothelium-derived NO (36). These
actions may partially explain our observation of improved
insulin sensitivity after CYP2J3 gene delivery. In addition,
we observed effects on insulin signaling in tissues directly
involved in insulin sensitivity (37–40), including liver,
muscle, heart, and kidney, as well as in an islet cell line.
Our data show that insulin-dependent signaling was signif-
icantly inhibited in fructose-treated rats and db/db mice,
but dramatically reversed by CYP2J3 overexpression.
These results indicate that CYP2J3 overexpression poten-
tiates insulin receptor signaling in liver, muscle, heart, and
kidney and thus improves insulin sensitivity.
We also evaluated the phosphorylation status of AMPK.
Small molecule–mediated activation of AMPK improves
insulin resistance in ob/ob mice (41) and represents a
promising approach for the treatment of type 2 diabetes
and metabolic syndrome (42). We found that CYP2J3
overexpression resulted in a signiﬁcant increase in AMPK
phosphorylation, which may contribute to the EET-medi-
ated alleviation of diabetes and insulin resistance we
observed. CYP2J3 overexpression induced a signiﬁcant
increase in urine cAMP and cGMP secretion, which may
result from GPCR activation by EETs. Thus, EET-induced
GPCR activation may play an important role in EET-
mediated AMPK activation and insulin sensitization.
Taken together, these data suggest that the improvement
of insulin resistance after CYP2J3 gene delivery was due
to, at least in part, increased activation of IR/IRS-1/PI
3-kinase/AKT and AMPK signaling pathways (43), as well
as the upregulation of eNOS.
In conclusion, we have demonstrated alleviation of
insulin resistance and diabetes by CYP2J3 gene therapy in
db/db diabetic mice and a model of fructose-induced
insulin resistance in rats. These effects were associated
with increased insulin sensitivity in peripheral tissues and
organs via upregulation of systemic eNOS and activation
of the IRS-1/PI 3-kinase/AKT and AMPK signaling path-
ways in muscle, liver, heart, kidney, and aorta. However,
the more precise mechanisms need to be further investi-
gated. The ability of CYP epoxygenase delivery to exert a
broad spectrum of beneﬁcial effects in these animal mod-
els warrants further investigation of this approach in the
treatment of hypertension associated with insulin resis-
tance and diabetes in humans.
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